亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer

埃罗替尼 医学 表皮生长因子受体 内科学 肺癌 肿瘤科 盐酸厄洛替尼 癌症 阶段(地层学) 不利影响 临床终点 胃肠病学 外科 临床试验 生物 古生物学
作者
Nathan A. Pennell,Joel W. Neal,Jamie E. Chaft,Christopher G. Azzoli,Pasi Antero Janne,Ramaswamy Govindan,Tracey L. Evans,Daniel Botelho Costa,Heather A. Wakelee,Rebecca Suk Heist,Marc A. Shapiro,Alona Muzikansky,Sudish C. Murthy,Michael D. Lanuti,Valerie W. Rusch,Mark G. Kris,Lecia Van Dam Sequist
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:37 (2): 97-104 被引量:211
标识
DOI:10.1200/jco.18.00131
摘要

PURPOSE: Given the pivotal role of epidermal growth factor receptor (EGFR) inhibitors in advanced EGFR-mutant non-small-cell lung cancer (NSCLC), we tested adjuvant erlotinib in patients with EGFR-mutant early-stage NSCLC. MATERIALS AND METHODS: edition of the American Joint Committee on Cancer staging system) EGFR-mutant NSCLC were treated with erlotinib 150 mg per day for 2 years after standard adjuvant chemotherapy with or without radiotherapy. The study was designed for 100 patients and powered to demonstrate a primary end point of 2-year disease-free survival (DFS) greater than 85%, improving on historic data of 76%. RESULTS: Patients (N = 100) were enrolled at seven sites from January 2008 to May 2012; 13% had stage IA disease, 32% had stage IB disease, 11% had stage IIA disease, 16% had stage IIB disease, and 28% had stage IIIA disease. Toxicities were typical of erlotinib; there were no grade 4 or 5 adverse events. Forty percent of patients required erlotinib dose reduction to 100 mg per day and 16% to 50 mg per day. The intended 2-year course was achieved in 69% of patients. The median follow-up was 5.2 years, and 2-year DFS was 88% (96% stage I, 78% stage II, 91% stage III). Median DFS and overall survival have not been reached; 5-year DFS was 56% (95% CI, 45% to 66%), 5-year overall survival was 86% (95% CI, 77% to 92%). Disease recurred in 40 patients, with only four recurrences during erlotinib treatment. The median time to recurrence was 25 months after stopping erlotinib. Of patients with recurrence who underwent rebiopsy (n = 24; 60%), only one had T790M mutation detected. The majority of patients with recurrence were retreated with erlotinib (n = 26; 65%) for a median duration of 13 months. CONCLUSION: Patients with EGFR-mutant NSCLC treated with adjuvant erlotinib had an improved 2-year DFS compared with historic genotype-matched controls. Recurrences were rare for patients receiving adjuvant erlotinib, and patients rechallenged with erlotinib after recurrence experienced durable benefit.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
369ninja发布了新的文献求助10
1秒前
可靠往事完成签到,获得积分10
3秒前
自由的梦山完成签到,获得积分10
13秒前
喜悦如萱完成签到,获得积分10
19秒前
21秒前
26秒前
369ninja发布了新的文献求助10
32秒前
45秒前
学霸业的应助被369ninja采纳,获得10
1分钟前
369ninja发布了新的文献求助10
1分钟前
1分钟前
43tg完成签到,获得积分10
1分钟前
qfhbg完成签到,获得积分10
1分钟前
落后哈密瓜完成签到,获得积分10
1分钟前
wetg完成签到,获得积分10
1分钟前
学霸业的应助被369ninja采纳,获得10
1分钟前
portik完成签到,获得积分10
1分钟前
要减肥的菀完成签到,获得积分10
1分钟前
hgjk完成签到,获得积分10
1分钟前
1分钟前
sdf完成签到,获得积分10
1分钟前
VDC的应助被369ninja采纳,获得30
1分钟前
amz完成签到,获得积分10
1分钟前
adefgv完成签到,获得积分10
1分钟前
科目三的应助被科研通管家采纳,获得10
1分钟前
fhjg完成签到,获得积分10
1分钟前
Nole的应助被369ninja采纳,获得10
1分钟前
jtk完成签到,获得积分10
1分钟前
pwn完成签到,获得积分10
1分钟前
2分钟前
虚心的手套完成签到,获得积分10
2分钟前
wh完成签到,获得积分10
2分钟前
369ninja发布了新的文献求助10
2分钟前
2分钟前
我是笨蛋完成签到 ,获得积分10
2分钟前
CodeCraft的应助被369ninja采纳,获得10
2分钟前
fsw完成签到,获得积分10
2分钟前
sd完成签到,获得积分10
2分钟前
安静白柏完成签到,获得积分10
2分钟前
li1完成签到,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179956
求助须知:如何正确求助?哪些是违规求助? 9570170
关于积分的说明 21808464
捐赠科研通 7775818
什么是DOI,文献DOI怎么找? 3433251
关于科研通互助平台的介绍 2557361
邀请新用户注册赠送积分活动 2478958